Therapeutic targets for medulloblastoma

Bibliography

• Kadin ME, Rubinstein LJ, Nelson JS. Neonatal cerebellar medulloblastoma originating from the fetal external granular layer. J Neuropathol Exp Neurol 1970;29:583-600
   PubMed Web of Science ®Google Scholar
• Marino S, Vooijs M, van Der Gulden H, et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004
   PubMed Web of Science ®Google Scholar
• Reddy AT, Packer RJ. Medulloblastoma. Curr Opin Neurol 1999;12:681-5
   PubMed Web of Science ®Google Scholar
• Hatten ME, Alder J, Zimmerman K, et al. Genes involved in cerebellar cell specification and differentiation. Curr Opin Neurobiol 1997;7:40-7
   PubMed Web of Science ®Google Scholar
• Jozwiak J, Grajkowska W, Wlodarski P. Pathogenesis of medulloblastoma and current treatment outlook. Med Res Rev 2007;27:869-90
   PubMed Web of Science ®Google Scholar
• Dahmane N, Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999;126:3089-100
   PubMed Web of Science ®Google Scholar
• Wallace VA. Purkinje-cell-derived Sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. Curr Biol 1999;9:445-8
   PubMed Web of Science ®Google Scholar
• Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999;22:103-14
   PubMed Web of Science ®Google Scholar
• Vorechovsky I, Tingby O, Hartman M, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997;15:361-6
   PubMed Web of Science ®Google Scholar
• Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10
   PubMed Web of Science ®Google Scholar
• Burke R, Nellen D, Bellotto M, et al. Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells. Cell 1999;99:803-15
   PubMed Web of Science ®Google Scholar
• Zhu AJ, Scott MP. Incredible journey: how do developmental signals travel through tissue? Genes Dev 2004;18:2985-97
   PubMed Web of Science ®Google Scholar
• Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15-28
   PubMed Web of Science ®Google Scholar
• Park HL, Bai C, Platt KA, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 2000;127:1593-605
   PubMed Web of Science ®Google Scholar
• Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001;15:3059-87
   PubMed Web of Science ®Google Scholar
• Varjosalo M, Li SP, Taipale J. Divergence of hedgehog signal transduction mechanism between Drosophila and mammals. Dev Cell 2006;10:177-86
   PubMed Web of Science ®Google Scholar
• Eggenschwiler JT, Anderson KV. Cilia and developmental signaling. Ann Rev Cell Dev Biol 2007;23:345-73
   PubMed Web of Science ®Google Scholar
• Huangfu D, Liu A, Rakeman AS, et al. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature 2003;426:83-7
   PubMed Web of Science ®Google Scholar
• Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004;428:337-41
   PubMed Web of Science ®Google Scholar
• Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-8
   PubMed Web of Science ®Google Scholar
• Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000;27:44-51
   PubMed Web of Science ®Google Scholar
• Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-13
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-61
   PubMed Web of Science ®Google Scholar
• Pazzaglia S, Tanori M, Mancuso M, et al. Two-hit model for progression of medulloblastoma preneoplasia in Patched heterozygous mice. Oncogene 2006;25:5575-80
   PubMed Web of Science ®Google Scholar
• Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001;61:513-6
   PubMed Web of Science ®Google Scholar
• Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994;54:5649-51
   PubMed Web of Science ®Google Scholar
• Di Marcotullio L, Ferretti E, De SE, et al. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA 2004;101:10833-8
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007;104:293-302
   PubMed Web of Science ®Google Scholar
• Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52
   PubMed Web of Science ®Google Scholar
• Akiyama T, Kawasaki Y. Wnt signalling and the actin cytoskeleton. Oncogene 2006;25:7538-44
   PubMed Web of Science ®Google Scholar
• Sheldahl LC, Park M, Malbon CC, et al. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol 1999;9:695-8
   PubMed Web of Science ®Google Scholar
• Kuhl M, Sheldahl LC, Malbon CC, et al. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem 2000;275:12701-11
   PubMed Web of Science ®Google Scholar
• Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the β-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 2004;131:5103-15
   PubMed Web of Science ®Google Scholar
• Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42
   PubMed Web of Science ®Google Scholar
• Molenaar M, van de Wetering M, Oosterwegel M, et al. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 1996;86:391-9
   PubMed Web of Science ®Google Scholar
• Meng X, Poon R, Zhang X, et al. Suppressor of fused negatively regulates β-catenin signaling. J Biol Chem 2001;276:40113-9
   PubMed Web of Science ®Google Scholar
• Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic β-catenin mutations. Cancer Res 1998;58:896-9
   PubMed Web of Science ®Google Scholar
• Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-7
   PubMed Web of Science ®Google Scholar
• Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445-9
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of β-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59:333-7
   PubMed Web of Science ®Google Scholar
• Baeza N, Masuoka J, Kleihues P, et al. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003;22:632-6
   PubMed Web of Science ®Google Scholar
• Kurihara M, Tokunaga Y, Ochi A, et al. Expression of insulin-like growth factor I receptors in human brain tumors: comparison with epidermal growth factor receptor by using quantitative autoradiography. No To Shinkei 1989;41:719-25
   PubMedGoogle Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42
   PubMed Web of Science ®Google Scholar
• Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000;275:28341-4
   PubMed Web of Science ®Google Scholar
• Glick RP, Unterman TG, Blaydes L, et al. Insulin-like growth factors in central nervous system tumors. Ann NY Acad Sci 1993;692:223-9
   PubMed Web of Science ®Google Scholar
• Nolan CM, Kyle JW, Watanabe H, et al. Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regul 1990;1:197-213
   PubMedGoogle Scholar
• Baserga R, Hongo A, Rubini M, et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18
   PubMed Web of Science ®Google Scholar
• Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002;8:1822-30
   PubMed Web of Science ®Google Scholar
• Ji Z, Mei FC, Xie J, et al. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007;282:14048-55
   PubMed Web of Science ®Google Scholar
• Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007;104:5895-900
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Langdon JA, Hollander A, et al. Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 2006;42:646-9
   PubMed Web of Science ®Google Scholar
• Di Carlo A, Mariano A, Macchia PE, et al. Epidermal growth factor receptor in human brain tumors. J Endocrinol Invest 1992;15:31-7
   PubMed Web of Science ®Google Scholar
• Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45
   PubMed Web of Science ®Google Scholar
• Bodey B, Kaiser HE, Siegel SE. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors. In vivo 2005;19:931-41
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80
   PubMed Web of Science ®Google Scholar
• Calabrese C, Frank A, Maclean K, et al. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERK. J Biol Chem 2003;278:24951-9
   PubMed Web of Science ®Google Scholar
• Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52
   PubMed Web of Science ®Google Scholar
• Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004
   PubMed Web of Science ®Google Scholar
• Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140-8
   PubMed Web of Science ®Google Scholar
• Wlodarski P, Grajkowska W, Lojek M, et al. Activation of Akt and Erk pathways in medulloblastoma. Folia Neuropathol 2006;44:214-20
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Brown KM, La Fleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52
   PubMed Web of Science ®Google Scholar
• Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25
   PubMed Web of Science ®Google Scholar
• van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005;11:496-502
   PubMed Web of Science ®Google Scholar
• Grabher C, von BH, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006;6:347-59
   PubMed Web of Science ®Google Scholar
• Solecki DJ, Liu XL, Tomoda T, et al. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 2001;31:557-68
   PubMed Web of Science ®Google Scholar
• Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-93
   PubMed Web of Science ®Google Scholar
• Lutolf S, Radtke F, Aguet M, et al. Notch1 is required for neuronal and glial differentiation in the cerebellum. Development 2002;129:373-85
   PubMed Web of Science ®Google Scholar
• Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999;18:5321-33
   PubMed Web of Science ®Google Scholar
• Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003;283:17-21
   PubMed Web of Science ®Google Scholar
• Knoepfler PS, Kenney AM. Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. Cell Cycle 2006;5:47-52
   PubMed Web of Science ®Google Scholar
• Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004;64:7794-800
   PubMed Web of Science ®Google Scholar
• Ingram WJ, McCue KI, Tran TH, et al. Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 2007. [Epub ahead of print]. Doi: 10.1038/sj.onc.1210767
   PubMedGoogle Scholar
• Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-9
   PubMed Web of Science ®Google Scholar
• Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003;21:1581-91
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-18
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J Clin Oncol 1999;17:832-45
   PubMed Web of Science ®Google Scholar
• Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390-6
   PubMed Web of Science ®Google Scholar
• Ribi K, Relly C, Landolt MA, et al. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 2005;36:357-65
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-60
   PubMed Web of Science ®Google Scholar
• Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001;95:82-8
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978-86
   PubMed Web of Science ®Google Scholar
• Kenney AM, Rowitch DH. Sonic hedgehog promotes G1;cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol 2000;20:9055-67
   PubMed Web of Science ®Google Scholar
• Jacobs WA, Sato Y. The veratrine alkaloids; a further study of the structure of veratramine and jervine. J Biol Chem 1949;181:55-65
   PubMed Web of Science ®Google Scholar
• Beachy PA, Cooper MK, Young KE, et al. Multiple roles of cholesterol in hedgehog protein biogenesis and signaling. Cold Spring Harb Symp Quant Biol 1997;62:191-204
   PubMedGoogle Scholar
• Lange Y, Ye J, Rigney M, et al. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res 1999;40:2264-70
   PubMed Web of Science ®Google Scholar
• Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-9
   PubMed Web of Science ®Google Scholar
• Chen JK, Taipale J, Cooper MK, et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16:2743-8
   PubMed Web of Science ®Google Scholar
• Williams JA, Guicherit OM, Zaharian BI, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003;100:4616-21
   PubMed Web of Science ®Google Scholar
• Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-40
   PubMed Web of Science ®Google Scholar
• Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 2005;65:4975-8
   PubMed Web of Science ®Google Scholar
• Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007;104:8455-60
   PubMed Web of Science ®Google Scholar
• Hinoda Y, Sasaki S, Ishida T, et al. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 2004;95:621-5
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11:7841-50
   PubMed Web of Science ®Google Scholar
• Geng L, Shinohara ET, Kim D, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006;64:263-71
   PubMed Web of Science ®Google Scholar
• Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003;304:1085-92
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14
   PubMedGoogle Scholar
• Stragliotto G, Vega F, Stasiecki P, et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32A:636-40
   PubMed Web of Science ®Google Scholar
• Kenney J, Schmiedl U, Maravilla K, et al. Measurement of blood-brain barrier permeability in a tumor model using magnetic resonance imaging with gadolinium-DTPA. Magn Reson Med 1992;27:68-75
   PubMed Web of Science ®Google Scholar
• Glass TL, Liu TJ, Yung WK. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol 2000;2:151-8
   PubMed Web of Science ®Google Scholar
• End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7
   PubMed Web of Science ®Google Scholar
• Sardi I, Cavalieri D, Massimino M. Emerging treatments and gene expression profiling in high-risk medulloblastoma. Paediatr Drugs 2007;9:81-96
   PubMedGoogle Scholar
• Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227
   PubMed Web of Science ®Google Scholar
• Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91
   PubMed Web of Science ®Google Scholar
• Pong K, Zaleska MM. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord 2003;2:349-56
   PubMedGoogle Scholar
• Hu X, Pandolfi PP, Li Y, et al. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005;7:356-68
   PubMed Web of Science ®Google Scholar
• Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-8
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006;79:141-52
   PubMedGoogle Scholar